Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA commissioner nomination

Executive Summary

The Senate Health Committee is understood to be planning a vote on FDA Acting Commissioner Lester Crawford's nomination to the permanent post for mid-May. The vote would come just over a month after an April 13 vote on Crawford was abruptly cancelled. At the time, committee staff said the cancellation was due to an eleventh-hour anonymous allegation about personal conduct that the leadership believed merited further investigation (1"The Pink Sheet" April 18, 2005, p. 4)...

You may also be interested in...

FDA Confirmation Process Hits A Roadblock: Time For Plan B?

Acting FDA Commissioner Lester Crawford's prospects for Senate confirmation appear to be in jeopardy after the Health Committee disclosed concerns about a conduct allegation lodged against the nominee

Illumina Will Pay $8Bn To Buy Back Cancer Screening Start-Up Grail

Illumina announced today it will buy back Grail to allow faster adoption of its liquid biopsy test.

Roche’s Ipatasertib Promising In Prostate, But Disappointing In Breast Cancer

Roche is hoping the investigational oral drug can help it expand its presence in breast cancer and break into the prostate cancer market – but the signals are decidedly mixed.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts